Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170566 | 0.80 | RAB9A (0.54) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL4640117 | 0.78 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL1012611 | 0.78 | NPC1 (0.49) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL4471861 | 0.76 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL2557713 | 0.76 | NPC1 (0.50) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL12282539 | 0.74 | NPC1 (0.48) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL16866570 | 0.73 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL15485199 | 0.73 | NPC1 (0.50) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL2571479 | 0.72 | RAB9A (0.49) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL28506730 | 0.70 | NPC1 (0.47) | RAB9ASMN1; SMN2NPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943243-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7652015-B2 | Suppression cytokines , tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080269244-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| CN-101296922-A | Kinase inhibitors | LILLY CO ELI (US) | 2008-10-29 | — | — | CN | disclosed |
| EP-1943243-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053394-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | CNKSR1, CHUK, SLC14A1 | RAB9A 698/4885SMN1; SMN2 4317/4885NPC1 1134/4885 |
| US-20080269244-A1 | Kinase Inhibitors | MAP3K1, MAP3K20, MAP3K19 | RAB9A 1018/4885SMN1; SMN2 3849/4885NPC1 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.